Your search returned 9 results.

Results
	1.	Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate. [electronic resource] by Dorshow, Richard B Bugaj, Joseph E Producer: 20200218 In: Regulatory toxicology and pharmacology : RTP vol. 107 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Dose enhancement through combining internalizing radiation and contrast media. [electronic resource] by Dinkelborg, Ludger M Bugaj, Joseph E Producer: 20070111 In: Cancer biotherapy & radiopharmaceuticals vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Pre-clinical toxicity evaluation of MB-102, a novel fluorescent tracer agent for real-time measurement of glomerular filtration rate. [electronic resource] by Bugaj, Joseph E Dorshow, Richard B Producer: 20160113 In: Regulatory toxicology and pharmacology : RTP vol. 72 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Novel approach in radionuclide tumor therapy: dose enhancement by high Z-element contrast agents. [electronic resource] by Aziz, Emad F Bugaj, Joseph E Caglar, Gül Dinkelborg, Ludger M Lawaczeck, Rüdiger Producer: 20070111 In: Cancer biotherapy & radiopharmaceuticals vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. [electronic resource] by Achilefu, Samuel Srinivasan, Ananthacari Schmidt, Michelle A Jimenez, Hermo N Bugaj, Joseph E Erion, Jack L Producer: 20030818 In: Journal of medicinal chemistry vol. 46 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. [electronic resource] by McKinley, Eliot T Bugaj, Joseph E Zhao, Ping Guleryuz, Saffet Mantis, Christine Gokhale, Prafulla C Wild, Robert Manning, H Charles Producer: 20111007 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. [electronic resource] by Li, Wen Ping Lewis, Jason S Kim, Joonyoung Bugaj, Joseph E Johnson, Michael A Erion, Jack L Anderson, Carolyn J Producer: 20030805 In: Bioconjugate chemistry vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. [electronic resource] by Achilefu, Samuel Jimenez, Hermo N Dorshow, Richard B Bugaj, Joseph E Webb, Elizabeth G Wilhelm, R Randy Rajagopalan, Raghavan Johler, Jill Erion, Jack L Producer: 20020531 In: Journal of medicinal chemistry vol. 45 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. [electronic resource] by Breeman, Wouter A P de Jong, Marion Erion, Jack L Bugaj, Joseph E Srinivasan, Ananth Bernard, Bert F Kwekkeboom, Dik J Visser, Theo J Krenning, Eric P Producer: 20030110 In: Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. 43 Availability: No items available. Save to lists Add to cart (remove)